Membrane-type metalloprotease inhibitory protein and pharmaceutical and pharmaceutical composition containing same, and respective uses thereof
US11851475B2 · kind B2 · utility
0Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 20, 2018 |
| Grant date | Dec 26, 2023 |
| Priority date | — |
| Expiry date | Jan 3, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/81
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a membrane-type metalloprotease inhibitory protein T1PrαTACE and use thereof, which can be used for preparing drugs targeting MT1-MMP or TACE endonuclease. Also disclosed are an antitumor pharmaceutical composition comprising BHK-21 cells and an artificial basal membrane which expresses T1PrαTACE protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.